3 Asian Penny Stocks With Market Caps Larger Than US$700M

As Asian markets navigate a period of economic shifts and evolving investor sentiment, the focus has increasingly turned to the potential of smaller-cap stocks. Penny stocks, while often seen as remnants of past market eras, continue to offer intriguing opportunities for investors seeking growth at accessible price points. By examining those with strong financial foundations and clear growth potential, we can uncover compelling investment prospects within this often overlooked segment.

Top 10 Penny Stocks In Asia

Name	Share Price	Market Cap	Rewards & Risks
YKGI (Catalist:YK9)	SGD0.149	SGD62.74M	✅ 2 ⚠️ 4 View Analysis >
Lever Style (SEHK:1346)	HK$1.38	HK$853.56M	✅ 4 ⚠️ 1 View Analysis >
Asia Medical and Agricultural Laboratory and Research Center (SET:AMARC)	THB2.64	THB1.11B	✅ 3 ⚠️ 3 View Analysis >
Plan B Media (SET:PLANB)	THB3.68	THB16.93B	✅ 5 ⚠️ 2 View Analysis >
TK Group (Holdings) (SEHK:2283)	HK$2.44	HK$2.02B	✅ 4 ⚠️ 1 View Analysis >
Panjawattana Plastic (SET:PJW)	THB2.02	THB1.17B	✅ 4 ⚠️ 2 View Analysis >
Atlantic Navigation Holdings (Singapore) (Catalist:5UL)	SGD0.128	SGD67.01M	✅ 2 ⚠️ 3 View Analysis >
Yangzijiang Shipbuilding (Holdings) (SGX:BS6)	SGD3.16	SGD12.44B	✅ 5 ⚠️ 1 View Analysis >
Livestock Improvement (NZSE:LIC)	NZ$1.01	NZ$143.77M	✅ 2 ⚠️ 3 View Analysis >
Scott Technology (NZSE:SCT)	NZ$2.85	NZ$240.51M	✅ 4 ⚠️ 0 View Analysis >

Click here to see the full list of 952 stocks from our Asian Penny Stocks screener.

We're going to check out a few of the best picks from our screener tool.

Fu Shou Yuan International Group (SEHK:1448)

Simply Wall St Financial Health Rating: ★★★★★★

Overview: Fu Shou Yuan International Group Limited, with a market cap of HK$6.02 billion, operates in the People's Republic of China offering burial and funeral services through its subsidiaries.

Operations: The company's revenue is primarily derived from burial services (CN¥1.28 billion) and funeral services (CN¥276.98 million), along with other services contributing CN¥37 million.

Market Cap: HK$6.02B

Fu Shou Yuan International Group, with a market cap of HK$6.02 billion, is currently unprofitable but maintains financial stability as its short-term assets of CN¥2.8 billion exceed both short and long-term liabilities. The company is debt-free, which alleviates concerns over interest payments and debt coverage by cash flow. Despite losses increasing at 12% annually over the past five years, earnings are forecast to grow significantly at 70% per year. Recent executive changes include appointing Mr. Ho Man as Chief Development Strategist and introducing a Co-CEO structure to enhance operational efficiency and strategic development alignment.

• Click to explore a detailed breakdown of our findings in Fu Shou Yuan International Group's financial health report.
• Learn about Fu Shou Yuan International Group's future growth trajectory here.

Tong Ren Tang Technologies (SEHK:1666)

Simply Wall St Financial Health Rating: ★★★★★☆

Overview: Tong Ren Tang Technologies Co. Ltd., along with its subsidiaries, produces and distributes Chinese medicine products in Mainland China and Hong Kong, with a market cap of approximately HK$5.66 billion.

Operations: The company's revenue is primarily derived from its main operations, generating CN¥4.16 billion, and its Chinese medicine segment, which contributes CN¥1.57 billion.

Market Cap: HK$5.66B

Tong Ren Tang Technologies, with a market cap of HK$5.66 billion, faces challenges from negative earnings growth over the past year and low return on equity at 7.7%. Despite this, it pays a reliable dividend of 4.45% and has strong financial health with short-term assets of CN¥11 billion exceeding both short-term and long-term liabilities. The company’s debt is well covered by operating cash flow, indicating sound debt management. Recent board changes include appointing Mr. Siu, Paul Yu Hay as an independent non-executive director and chairman of the Audit Committee to potentially strengthen governance amidst its relatively inexperienced board and management team.

• Click here to discover the nuances of Tong Ren Tang Technologies with our detailed analytical financial health report.
• Gain insights into Tong Ren Tang Technologies' outlook and expected performance with our report on the company's earnings estimates.

BrainAurora Medical Technology (SEHK:6681)

Simply Wall St Financial Health Rating: ★★★★☆☆

Overview: BrainAurora Medical Technology Limited offers system integral software solutions for hospitals and research projects in Mainland China, with a market cap of HK$6.18 billion.

Operations: The company generates revenue primarily from providing system integral software solutions, amounting to CN¥135.16 million, and research projects, contributing CN¥10.37 million.

Market Cap: HK$6.18B

BrainAurora Medical Technology, with a market cap of HK$6.18 billion, recently completed a follow-on equity offering raising HK$515.2 million, indicating robust capital acquisition efforts. The company's strategic alliances with Peking University Sixth Hospital and Shandong Mental Health Center aim to advance digital therapeutics in mental health, enhancing its R&D capabilities and commercialization prospects. Despite being unprofitable with negative return on equity at -85.6%, BrainAurora's revenue is forecasted to grow 32.93% annually, supported by sufficient cash runway for over a year and manageable net debt to equity ratio at 6.7%.

• Click here and access our complete financial health analysis report to understand the dynamics of BrainAurora Medical Technology.
• Explore BrainAurora Medical Technology's analyst forecasts in our growth report.

Make It Happen

• Gain an insight into the universe of 952 Asian Penny Stocks by clicking here.
• Looking For Alternative Opportunities? Uncover 14 companies that survived and thrived after COVID and have the right ingredients to survive Trump's tariffs.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com